Financing ·
Abbott Laboratories shareholders approved the 2026 Incentive Stock Program, which authorizes the issuance of up to 140…
ABTAbbott Laboratories
Abbott Laboratories shareholders approved the 2026 Incentive Stock Program, which authorizes the issuance of up to 140 million common shares to replace the company's existing 2017 program. Additionally, the company expanded its Board of Directors to thirteen members and appointed Kevin Conroy to the Board. These updates refresh Abbott's equity compensation framework and governance structure for the upcoming ten-year term.